CAPLYTA Shows Largest 4.71-Point MADRS Reduction and Zero Weight Gain
Johnson & Johnson’s CAPLYTA ranked highest among five adjunctive MDD treatments in a network meta-analysis, with a mean MADRS reduction of 4.71 points and odds ratios of 2.33 for response and 2.22 for remission. CAPLYTA showed no significant weight gain (mean change –0.08) and the lowest akathisia risk.
1. Network Meta-Analysis Design
Johnson & Johnson conducted a network meta-analysis of 10 randomized controlled trials evaluating five FDA-approved adjunctive atypical antipsychotics for major depressive disorder, using placebo plus antidepressant therapy as the anchor to compare efficacy and safety outcomes.
2. Efficacy Outcomes
CAPLYTA produced the largest mean reduction in MADRS score (–4.71; 95% CrI –5.78 to –3.63) and the highest odds of MADRS response (OR 2.33) and remission (OR 2.22) among all treatments, alongside a mean CGI-S score reduction of –0.60.
3. Safety and Tolerability Findings
On safety measures, CAPLYTA demonstrated no significant weight gain (mean change –0.08; 77% probability of superiority) and the lowest risk of ≥7% weight increase (OR 0.41). It was the only treatment with akathisia risk comparable to placebo (OR 3.78) and showed variable somnolence risk versus other therapies.